BIO - Bio-Rad Laboratories Inc Stock Price, Fair Value and News

319.70USD+4.53 (+1.44%)Market Closed

Market Summary

USD319.70+4.53

Market Closed

1.44%

BIO Stock Price

View Fullscreen

BIO RSI Chart

BIO Valuation

Market Cap

9.1B

Price/Earnings (Trailing)

-28.28

Price/Sales (Trailing)

3.5

EV/EBITDA

-25.06

Price/Free Cashflow

49.15

BIO Price/Sales (Trailing)

BIO Profitability

EBT Margin

-17.04%

Return on Equity

-3.56%

Return on Assets

-2.56%

Free Cashflow Yield

2.03%

BIO Fundamentals

BIO Revenue

Revenue (TTM)

2.6B

Rev. Growth (Yr)

-9.75%

Rev. Growth (Qtr)

-10.33%

BIO Earnings

Earnings (TTM)

-322.4M

Earnings Growth (Yr)

456.71%

Earnings Growth (Qtr)

9.78%

Breaking Down BIO Revenue

Last 7 days

4.9%

Last 30 days

12.4%

Last 90 days

14.2%

Trailing 12 Months

-25.4%

How does BIO drawdown profile look like?

BIO Financial Health

Current Ratio

6.57

Debt/Equity

0.13

Debt/Cashflow

0.29

BIO Investor Care

Buy Backs (1Y)

3.64%

Diluted EPS (TTM)

-10.36

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	2.6B	0	0	0
2023	2.8B	2.8B	2.7B	2.7B
2022	2.9B	2.9B	2.8B	2.8B
2021	2.7B	2.9B	3.0B	2.9B
2020	2.3B	2.3B	2.4B	2.5B
2019	2.3B	2.3B	2.3B	2.3B
2018	2.2B	2.3B	2.3B	2.3B
2017	2.1B	2.1B	2.1B	2.2B
2016	2.0B	2.0B	2.1B	2.1B
2015	2.1B	2.1B	2.0B	2.0B
2014	2.1B	2.2B	2.2B	2.2B
2013	2.1B	2.1B	2.1B	2.1B
2012	2.1B	2.1B	2.0B	2.1B
2011	2.0B	2.0B	2.1B	2.1B
2010	1.8B	1.9B	1.9B	1.9B
2009	0	1.8B	1.8B	1.8B
2008	0	0	0	1.8B

Get all data in R, Python etc through our Historical Stock Data APIs

About Bio-Rad Laboratories Inc

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

CEO	Mr. Norman D. Schwartz
WEBSITE	bio-rad.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	8200

Bio-Rad Laboratories Inc Frequently Asked Questions

What is the ticker symbol for Bio-Rad Laboratories Inc? What does BIO stand for in stocks?

BIO is the stock ticker symbol of Bio-Rad Laboratories Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Bio-Rad Laboratories Inc (BIO)?

As of Thu Jul 25 2024, market cap of Bio-Rad Laboratories Inc is 8.99 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BIO stock?

You can check BIO's fair value in chart for subscribers.

Is Bio-Rad Laboratories Inc a good stock to buy?

The fair value guage provides a quick view whether BIO is over valued or under valued. Whether Bio-Rad Laboratories Inc is cheap or expensive depends on the assumptions which impact Bio-Rad Laboratories Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BIO.

What is Bio-Rad Laboratories Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 25 2024, BIO's PE ratio (Price to Earnings) is -27.87 and Price to Sales (PS) ratio is 3.45. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BIO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Bio-Rad Laboratories Inc's stock?

In the past 10 years, Bio-Rad Laboratories Inc has provided 0.104 (multiply by 100 for percentage) rate of return.